Photocure ASA: Board Update

Published: 9 August 2013Organisational Announcements



Oslo, Norway, August 8, 2013: Photocure ASA (OSE: PHO), a specialty pharmaceutical company focused on photodynamic technologies in dermatology and cancer, announced today that Ingrid Wiik, a member of Photocure's board of director's since 2011, has sadly passed away.

Åse Aulie Michelet, Chairman of the Board of Photocure said, "On behalf of the Board of Directors and the employees of Photocure, we extend our deepest sympathies to Ingrid's family. Ingrid has played an integral role in the growth and success of Photocure and we thank her for the many contributions she has made."

Ingrid Wiik has spent more than 40 years in the pharmaceutical industry, both in R&D and general management, and has extensive leadership and international experience. She was President and CEO of Alpharma Inc. (listed on NYSE). She has also held several board positions including: Algeta ASA, Diagenic ASA, Coloplast AS (Denmark), Human Care (Sweden), Norske Skog ASA, Biotec Pharmacon ASA, Statoil ASA and Alpharma Inc.

For further information, please contact:
 
Photocure
President & CEO Kjetil Hestdal
Tel: + 47 913 19 535, Email: kh@photocure.no

This information is subject of the disclosure requirements acc. to §5-12 vphl (Norwegian Securities Trading Act)

News and events

Key InformationProviding an update on the XYZ incident

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do